Erratum: The elevation in maternal anti-angiogenic factors is independent of markers of neutrophil activation and systemic inflammation in preeclampsia (Angiogenesis)

Angiogenesis

Volumn 15, Issue 3, 2012, Pages 341-348

  Ramma, Wenda ^a   Buhimschi, Irina A ^b   Zhao, Guomao ^b   Dulay, Antonette T ^b   Nayeri, Unzila Ali ^b   Buhimschi, Catalin S ^b   Ahmed, Asif ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b YALE UNIVERSITY   (United States)

Author keywords

Inflammation; Neutrophil; Placenta growth factor; Preeclampsia; Soluble endoglin; Soluble Flt 1

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL;

EID: 84865153563     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9273-1     Document Type: Erratum

References (42)

1. Hogberg U (2005) The World Health Report 2005: "make every mother and child count"-including Africans. Scand J Public Health 33:409-411 (Pubitemid 43115054)
2. Ahmed A, Cudmore MJ (2009) Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem Soc Trans 37:1237-1242
3. Redman CW, Sacks GP, Sargent IL (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180:499-506 (Pubitemid 29093892)
4. Redman CW, Sargent IL (2009) Placental stress and pre-eclampsia: a revised view. Placenta 30(Suppl A):S38-42
5. Ahmed A, Dunk C, Kniss D, Wilkes M (1997) Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 76:779-791 (Pubitemid 27260345)
6. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E (2000) Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 95:353-357 (Pubitemid 30100498)
7. Ahmad S, Ahmed A (2001) Regulation of soluble VEGFR-1 by VEGF and oxygen and its elevation in pre-eclampsia and fetal growth restriction. Placenta 22:A.7
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658 (Pubitemid 36278583)
9. Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884-891 (Pubitemid 39435003)
10. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves A, Grone HJ et al (2010) Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14:1857-1867
11. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GD, Saade GR (2010) Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 116:114-120
12. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642-649 (Pubitemid 43865232)
13. Walshe TE, Dole VS, Maharaj AS, Patten IS, Wagner DD, D'Amore PA (2009) Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 29:1185-1192
14. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672-683 (Pubitemid 38364626)
15. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992-1005 (Pubitemid 44343543)
16. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM et al (2005) Urinary placental growth factor and risk of preeclampsia. JAMA 293:77-85 (Pubitemid 40066702)
17. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA (2005) Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 192:734-741 (Pubitemid 40311263)
18. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH (2008) Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 32:871-876
19. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH (2010) Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol 35:680-687
20. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ (2010) Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122:478-487
21. Savill J (1993) The fate of the neutrophil in vasculitis. Clin Exp Immunol 93(Suppl 1):2-5
22. Clark P, Boswell F, Greer IA (1998) The neutrophil and preeclampsia. Semin Reprod Endocrinol 16:57-64 (Pubitemid 28285304)
23. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW (2003) Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 59:153-160 (Pubitemid 36945233)
24. Greer IA, Dawes J, Johnston TA, Calder AA (1991) Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet Gynecol 78:28-32
25. Holthe MR, Staff AC, Berge LN, Fagerhol MK, Lyberg T (2005) Calprotectin plasma level is elevated in preeclampsia. Acta Obstet Gynecol Scand 84:151-154 (Pubitemid 40278803)
26. Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A (2010) The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol 151:3-9
27. Tosun M, Celik H, Avci B, Yavuz E, Alper T, Malatyalioglu E (2010) Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. J Matern Fetal Neonatal Med 23:880-886
28. Szarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11:59
29. Hadlock FP, Deter RL, Harrist RB, Park SK (1983) Computer assisted analysis of fetal age in the third trimester using multiple fetal growth parameters. J Clin Ultrasound 11:313-316 (Pubitemid 13037403)
30. ACOG: ACOG practice bulletin (2002) Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99:159-167
31. Buhimschi CS, Magloire L, Funai E, Norwitz ER, Kuczynski E, Martin R, Richman S, Guller S, Lockwood CJ, Buhimschi IA (2006) Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet Gynecol 107:1103-1113
32. Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M, Bahn S (2008) Increased alpha-defensins as a blood marker for schizophrenia susceptibility. Mol Cell Proteomics 7:1204-1213 (Pubitemid 352038267)
33. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK (1989) Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161:1200-1204 (Pubitemid 20007682)
34. Prieto JA, Panyutich AV, Heine RP (1997) Neutrophil activation in preeclampsia. Are defensins and lactoferrin elevated in preeclamptic patients? J Reprod Med 42:29-32 (Pubitemid 27053449)
35. Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC (2005) Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. Am J Obstet Gynecol 193:227-233 (Pubitemid 40991850)
36. Luppi P, Tse H, Lain KY, Markovic N, Piganelli JD, DeLoia JA (2006) Preeclampsia activates circulating immune cells with engagement of the NF-kappaB pathway. Am J Reprod Immunol 56:135-144
37. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK (2007) Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 197(176):e171-176
38. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A (2010) Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 47:1500-1506
39. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM (2010) The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 117:456-462
40. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE (2006) Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203:2165-2175 (Pubitemid 44352237)
41. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C et al (2011) Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124:940-950
42. Amorim MM, Santos LC, Faundes A (1999) Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 180:1283-1288 (Pubitemid 29259030)